Sonoma Pharmaceuticals (SNOA) 10-Q 5 Feb 25 2025 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2024	Feb. 04, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--03-31
Entity File Number	001-33216
Entity Registrant Name	SONOMA PHARMACEUTICALS, INC.
Entity Central Index Key	0001367083
Entity Tax Identification Number	68-0423298
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	5445 Conestoga Court
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	800
Local Phone Number	759-9305
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	SNOA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,615,765

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Current assets:
Cash and cash equivalents	$ 5,236	$ 3,128
Accounts receivable, net	2,405	2,898
Inventories, net	3,143	2,719
Prepaid expenses and other current assets	1,387	3,541
Current portion of deferred consideration, net of discount	209	262
Total current assets	12,380	12,548
Property and equipment, net	215	365
Operating lease, right of use assets	119	286
Deferred tax asset	760	1,145
Deferred consideration, net of discount, less current portion	121	330
Other assets	73	66
Total assets	13,668	14,740
Current liabilities:
Accounts payable	1,395	607
Accrued expenses and other current liabilities	1,916	2,113
Deferred revenue, current portion	302	478
Short-term debt	0	323
Operating lease liabilities, current portion	90	198
Total current liabilities	3,703	3,719
Deferred revenue, net of current portion	30	87
Withholding tax payable	5,036	4,710
Operating lease liabilities, less current portion	29	87
Total liabilities	8,798	8,603
Commitments and Contingencies (Note 5)
Stockholders’ Equity:
Preferred stock, $0.0001 par value; 714,286 shares authorized at December 31, 2024 and March 31, 2024, no shares issued and outstanding at December 31, 2024 and March 31, 2024	0	0
Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at December 31, 2024 and March 31, 2024, respectively, 1,615,765 and 780,371 shares issued and outstanding at December 31, 2024 and March 31, 2024, respectively (Note 1) (Note 7)	0	0
Additional paid-in capital	206,454	203,209
Accumulated deficit	(197,030)	(194,349)
Accumulated other comprehensive loss	(4,554)	(2,723)
Total stockholders’ equity	4,870	6,137
Total liabilities and stockholders’ equity	$ 13,668	$ 14,740

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Mar. 31, 2024
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	714,286	714,286
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	24,000,000
Common stock, shares issued	1,615,765	780,371
Common stock, shares outstanding	1,615,765	780,371

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Revenues	$ 3,564	$ 3,138	$ 10,534	$ 9,296
Cost of revenues	2,294	1,678	6,597	5,642
Gross profit	1,270	1,460	3,937	3,654
Operating expenses:
Research and development	427	601	1,403	1,462
Selling, general and administrative	1,874	1,703	5,588	5,484
Total operating expenses	2,301	2,304	6,991	6,946
Loss from operations	(1,031)	(844)	(3,054)	(3,292)
Other income (expense), net	112	(79)	675	(380)
Loss from operations before income taxes	(919)	(923)	(2,379)	(3,672)
Income tax (expense) benefit	(9)	57	(302)	(96)
Net loss	$ (928)	$ (866)	$ (2,681)	$ (3,768)
Net loss per share: basic	$ (0.63)	$ (1.59)	$ (2.40)	$ (10.74)
Net loss per share: diluted	$ (0.63)	$ (1.59)	$ (2.40)	$ (10.74)
Weighted-average number of shares: basic	1,464	546	1,117	351
Weighted-average number of shares: diluted	1,464	546	1,117	351
Other comprehensive loss:
Foreign currency translation adjustments	$ (357)	$ 297	$ (1,831)	$ 595
Comprehensive loss	$ (1,285)	$ (569)	$ (4,512)	$ (3,173)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (2,681)	$ (3,768)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	107	135
Stock-based compensation	134	447
Deferred income taxes	169	92
Changes in operating assets and liabilities:
Accounts receivable, net	219	(221)
Inventories, net	(679)	(93)
Prepaid expenses and other current assets	1,547	546
Deferred consideration	142	161
Operating lease, right-of-use assets	136	99
Accounts payable	864	(12)
Accrued expenses and other current liabilities	(1)	(226)
Deferred revenue	(140)	33
Withholding tax payable	326	356
Operating lease liabilities	(136)	(99)
Net cash provided by (used in) operating activities	7	(2,550)
Cash flows from investing activities:
Purchases of property and equipment	(33)	(20)
Net cash used in investing activities	(33)	(20)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering expenses	3,079	1,441
Proceeds from exercise of employee stock options	33	0
Payments for fractional shares related to reverse-split	(1)	0
Principal payments on short-term debt	(323)	(387)
Net cash provided by financing activities	2,788	1,054
Effect of exchange rate on cash and cash equivalents	(654)	102
Net increase (decrease) in cash and cash equivalents	2,108	(1,414)
Cash and cash equivalents, beginning of period	3,128	3,820
Cash and cash equivalents, end of period	5,236	2,406
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 8	$ 15

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Mar. 31, 2023		$ 200,909	$ (189,514)	$ (3,418)	$ 7,977
Beginning balance, shares at Mar. 31, 2023	246,678
Cost in connection with ATM		(5)			(5)
Employee stock-based compensation expenses		177			177
Employee stock-based compensation expenses, shares	10,402
Foreign currency translation adjustment				511	511
Net loss			(1,418)		(1,418)
Ending balance, value at Jun. 30, 2023		201,081	(190,932)	(2,907)	7,242
Ending balance, shares at Jun. 30, 2023	257,080
Beginning balance, value at Mar. 31, 2023		200,909	(189,514)	(3,418)	7,977
Beginning balance, shares at Mar. 31, 2023	246,678
Net loss					(3,768)
Ending balance, value at Dec. 31, 2023		202,797	(193,282)	(2,823)	6,692
Ending balance, shares at Dec. 31, 2023	684,217
Beginning balance, value at Jun. 30, 2023		201,081	(190,932)	(2,907)	7,242
Beginning balance, shares at Jun. 30, 2023	257,080
Employee stock-based compensation expenses		130			130
Employee stock-based compensation expenses, shares	1,887
Foreign currency translation adjustment				(213)	(213)
Net loss			(1,484)		(1,484)
Ending balance, value at Sep. 30, 2023		201,211	(192,416)	(3,120)	5,675
Ending balance, shares at Sep. 30, 2023	258,967
Proceeds from stock offering, net of offering expenses		1,446			1,446
Proceeds from stock offering, net of offering expenses, shares	425,000
Employee stock-based compensation expenses		140			140
Employee stock-based compensation expenses, shares	250
Foreign currency translation adjustment				297	297
Net loss			(866)		(866)
Ending balance, value at Dec. 31, 2023		202,797	(193,282)	(2,823)	6,692
Ending balance, shares at Dec. 31, 2023	684,217
Beginning balance, value at Mar. 31, 2024		203,209	(194,349)	(2,723)	6,137
Beginning balance, shares at Mar. 31, 2024	780,371
Proceeds from At-the-Market sale of common stock, net of offering expenses		748			748
Proceeds from At-the-Market sale of common stock, net of offering expenses, shares	158,311
Proceeds from exercise of employee stock options		7			7
Proceeds from exercise of employee stock options, shares	2,000
Employee stock-based compensation expenses		107			107
Employee stock-based compensation expenses, shares	9,538
Foreign currency translation adjustment				(881)	(881)
Net loss			(1,143)		(1,143)
Ending balance, value at Jun. 30, 2024		204,071	(195,492)	(3,604)	4,975
Ending balance, shares at Jun. 30, 2024	950,220
Beginning balance, value at Mar. 31, 2024		203,209	(194,349)	(2,723)	6,137
Beginning balance, shares at Mar. 31, 2024	780,371
Net loss					(2,681)
Ending balance, value at Dec. 31, 2024		206,454	(197,030)	(4,554)	4,870
Ending balance, shares at Dec. 31, 2024	1,615,765
Beginning balance, value at Jun. 30, 2024		204,071	(195,492)	(3,604)	4,975
Beginning balance, shares at Jun. 30, 2024	950,220
Proceeds from At-the-Market sale of common stock, net of offering expenses		1,541			1,541
Proceeds from At-the-Market sale of common stock, net of offering expenses, shares	381,433
Proceeds from exercise of employee stock options		26			26
Proceeds from exercise of employee stock options, shares	7,250
Payments for fractional shares related to reverse-split		(1)			(1)
Payments for fractional shares related to reverse-split, shares	(288)
Employee stock-based compensation expenses		14			14
Foreign currency translation adjustment				(593)	(593)
Net loss			(610)		(610)
Ending balance, value at Sep. 30, 2024		205,651	(196,102)	(4,197)	5,352
Ending balance, shares at Sep. 30, 2024	1,338,615
Proceeds from At-the-Market sale of common stock, net of offering expenses		790			790
Proceeds from At-the-Market sale of common stock, net of offering expenses, shares	277,150
Employee stock-based compensation expenses		13			13
Foreign currency translation adjustment				(357)	(357)
Net loss			(928)		(928)
Ending balance, value at Dec. 31, 2024		$ 206,454	$ (197,030)	$ (4,554)	$ 4,870
Ending balance, shares at Dec. 31, 2024	1,615,765

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (928)	$ (610)	$ (1,143)	$ (866)	$ (1,484)	$ (1,418)	$ (2,681)	$ (3,768)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Organization and Recent Develop

Organization and Recent Developments	9 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Recent Developments	Note 1. Organization and Recent Developments Organization Sonoma Pharmaceuticals, Inc. (the “Company”) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware in December 2006. The Company moved its principal office from Petaluma, California to Woodstock, Georgia in June 2020 and to Boulder, Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (“HOCl”) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal health care, and as a non-toxic disinfectant. The Company’s products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The Company sells its products either directly or via partners in 55 countries worldwide. Reverse Stock Split Effective August 29, 2024, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every twenty shares of common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each fractional share was settled with cash. The reverse stock split reduced the number of shares of the Company’s common stock outstanding from 21,174,693 to 1,058,447. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the common stock continues to be $0.0001. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended March 31, 2024, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on June 17, 2024.

Liquidity and Financial Conditi

Liquidity and Financial Condition	9 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Financial Condition	Note 2. Liquidity and Financial Condition The Company reported a net loss of $ 928,000 866,000 2,681,000 3,768,000 197,030,000 194,349,000 8,677,000 8,829,000 5,236,000 3,128,000 7,000 2,550,000 Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that new financings will be available on commercially acceptable terms, if needed. If the economic climate in the U.S. deteriorates, the Company’s ability to raise additional capital could be negatively impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. This uncertainty along with the Company’s history of losses indicates that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly. Net Loss per Share The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The following table provides the net loss for each period along with the computation of basic and diluted net loss per share: Schedule of computation of basic and diluted net loss per share Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2024 2023 2024 2023 Numerator: Net loss $ (928 ) $ (866 ) $ (2,681 ) $ (3,768 ) Denominator: Weighted-average number of common shares outstanding: basic and diluted 1,464 546 1,117 351 Net loss per share: basic and diluted $ (0.63 ) $ (1.59 ) $ (2.40 ) $ (10.74 ) The computation of basic loss per share for the three and nine months ended December 31, 2024 and 2023 excludes potentially dilutive securities because their inclusion would be anti-dilutive. The Company excluded from the computation of basic loss per share stock options of 42,000 51,000 42,000 51,000 Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology and products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. For all of the Company’s sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned. The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program. Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor. The Company evaluates the creditworthiness of new customers and monitors the creditworthiness of its existing customers to determine whether an event or changes in their financial circumstances would raise doubt as to the collectability of a sale at the time in which a sale is made. Payment terms on sales are generally 30 to 90 days. The Company assessed the promised goods and services in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation. Accounts Receivable Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends. The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company did not deem it necessary to record an allowance for doubtful accounts for probable credit losses at December 31, 2024 and March 31, 2024. At December 31, 2024 and March 31, 2024, the Company has allowances of $ 15,000 27,000 Inventories Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value. Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At December 31, 2024 and March 31, 2024, the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $ 239,000 296,000 Recent Accounting Standards Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.

Condensed Consolidated Balanc_3

Condensed Consolidated Balance Sheet	9 Months Ended
	Dec. 31, 2024
Schedules of balance sheet items
Condensed Consolidated Balance Sheet	Note 4. Condensed Consolidated Balance Sheet Inventories, net Inventories, net consist of the following: Schedule of inventories, net December 31, March 31, 2024 2024 Raw materials $ 1,376,000 $ 1,802,000 Finished goods 2,006,000 1,213,000 Inventories, gross 3,382,000 3,015,000 Less: allowance for obsolete and excess inventory (239,000 ) (296,000 ) Total inventories, net $ 3,143,000 $ 2,719,000 Leases The Company’s operating leases are comprised primarily of facility leases. Balance sheet information related to the Company’s leases is presented below: Schedule of lease information December 31, March 31, 2024 2024 Operating leases: Operating lease right-of-use assets $ 119,000 $ 286,000 Operating lease liabilities – current 90,000 198,000 Operating lease liabilities – non-current 29,000 87,000 Other information related to leases is presented below: Nine Months Ended December 31, 2024 Operating lease cost $ 277,000 Other information: Operating cash flows from operating leases (136,000 ) Weighted-average remaining lease term – operating leases (in months) 17.50 Weighted-average discount rate – operating leases 6.00 As of December 31, 2024, the annual minimum lease payments of our operating lease liabilities were as follows: Schedule of minimum lease payments of operating lease liabilities For Years Ending March 31, 2025 (excluding the nine months ended December 31, 2024) $ 41,000 2026 65,000 2027 14,000 2028 8,000 Total future minimum lease payments, undiscounted 128,000 Less: imputed interest (9,000 ) Present value of future minimum lease payments $ 119,000

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 5. Commitments and Contingencies Legal Matters The Company may be involved in legal matters arising in the ordinary course of business including matters involving proprietary technology from time to time. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss. Employment Matters The Company has employment agreements in place with two of its key executives. These executive employment agreements provide, among other things, for the payment of up to eighteen months of severance compensation for terminations under certain circumstances. As of December 31, 2024, with respect to these agreements, aggregated annual salaries was $ 586,000 1,300,000

Debt

Debt	9 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Debt	Note 6. Debt Financing of Insurance Premiums On February 6, 2024, the Company entered into a note agreement for $ 373,000 8.42 November 1, 2024 nine monthly installment payments 42,000 March 1, 2024 November 1, 2024 323,000

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Stockholders’ Equity	Note 7. Stockholders’ Equity Authorized Capital Effective August 29, 2024, the Company increased its authorized shares from 24,000,000 50,000,000 0.0001 714,286 0.0001 Sale of Common Stock In connection with the Equity Distribution Agreement that the Company entered into on December 15, 2023 with Maxim Group LLC (“Maxim”), as amended, from May 13, 2024 to November 20, 2024 the Company sold 816,894 3,325,000 3,079,000

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 8. Stock-Based Compensation For the three months ended December 31, 2024 and 2023, the Company incurred $ 13,000 140,000 134,000 447,000 At December 31, 2024, there was unrecognized compensation costs of $ 216,000 1.54 Stock options award activity is as follows: Schedule of stock options award activity Number of Weighted- Outstanding at April 1, 2024 51,675 $ 62.60 Options exercised (9,250 ) 3.60 Options forfeited (250 ) 3.60 Options expired (63 ) 1,836.29 Outstanding at December 31, 2024 42,112 $ 73.69 Exercisable at December 31, 2024 31,282 $ 95.17 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock, or $ 2.69 Restricted stock award activity is as follows: Schedule of restricted stock award activity Number of Shares Weighted Average Award Date Fair Value per Share Unvested restricted stock awards outstanding at April 1, 2024 – $ – Restricted stock awards granted 9,538 4.08 Restricted stock awards vested (9,538 ) 4.08 Unvested restricted stock awards outstanding at December 31, 2024 – $ – The Company issues new shares of common stock upon exercise of stock options or release of restricted stock awards.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes At the end of each interim reporting period, the Company determines the income tax provision by using an estimate of the annual effective tax rate, adjusted for discrete items occurring in the quarter. Our effective tax rate for the three and nine months ended December 31, 2024 was (0.1) (12.7) Judgment is required in determining whether deferred tax assets will be realized in full or in part. Management assesses the available positive and negative evidence on a jurisdictional basis to estimate if deferred tax assets will be recognized and when it is more likely than not that all or some deferred tax assets will not be realized, and a valuation allowance must be established. As of December 31, 2024, the Company continues to maintain a valuation allowance in the U.S.

Revenue Disaggregation

Revenue Disaggregation	9 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue Disaggregation	Note 10. Revenue Disaggregation The Company generates product revenues from products which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services which are provided to medical device manufacturers. The following table presents the Company’s disaggregated revenues by revenue source: Schedule of disaggregated revenues by revenue source Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Human Care $ 3,052,000 $ 2,461,000 $ 8,886,000 $ 7,286,000 Animal Care 376,000 621,000 1,176,000 1,688,000 Service and Royalty 136,000 56,000 472,000 322,000 $ 3,564,000 $ 3,138,000 $ 10,534,000 $ 9,296,000 The following table shows the Company’s revenues by geographic region: Schedule of revenues by geographic region Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 United States $ 614,000 $ 868,000 $ 1,930,000 $ 2,214,000 Europe 1,257,000 1,217,000 3,943,000 3,488,000 Asia 579,000 522,000 1,832,000 1,730,000 Latin America 829,000 368,000 2,174,000 1,165,000 Rest of the World 285,000 163,000 655,000 699,000 Total $ 3,564,000 $ 3,138,000 $ 10,534,000 $ 9,296,000

Significant Customer Concentrat

Significant Customer Concentrations	9 Months Ended
	Dec. 31, 2024
Risks and Uncertainties [Abstract]
Significant Customer Concentrations	Note 11. Significant Customer Concentrations The following table shows major customers revenues as a percentage of net revenue: Schedule of customer concentrations of risk Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Customer A – *% 11 – *% 12 Customer B 23 17 21 15 Customer C 19 13 19 15 The following table shows major customers accounts receivable balances as a percentage of net accounts receivables: December 31, 2024 2023 Customer A 19 13 Customer B – *% 15 Customer C 14 – *% Customer D 25 13 * % Represents less than 10%

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 12. Subsequent Events On January 2, 2025 the Company granted an aggregate of 22,500 stock options to the independent members of its Board of Directors. The options vest in equal annual increments over a three year period and have an exercise price of $2.68. Additionally, on January 2, 2025 the Company granted an aggregate of 27,000 stock options to its employees. The options are immediately vested on the grant date and have an exercise price of $2.68. Additionally, on January 2, 2025 the Company issued an aggregate of 45,000 restricted stock units to the members of its management group. The restricted stock units vest in equal increments over a two year period with the first vest date to occur on July 2, 2025.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.
Net Loss per Share	Net Loss per Share The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The following table provides the net loss for each period along with the computation of basic and diluted net loss per share: Schedule of computation of basic and diluted net loss per share Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2024 2023 2024 2023 Numerator: Net loss $ (928 ) $ (866 ) $ (2,681 ) $ (3,768 ) Denominator: Weighted-average number of common shares outstanding: basic and diluted 1,464 546 1,117 351 Net loss per share: basic and diluted $ (0.63 ) $ (1.59 ) $ (2.40 ) $ (10.74 ) The computation of basic loss per share for the three and nine months ended December 31, 2024 and 2023 excludes potentially dilutive securities because their inclusion would be anti-dilutive. The Company excluded from the computation of basic loss per share stock options of 42,000 51,000 42,000 51,000
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology and products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. For all of the Company’s sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned. The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program. Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor. The Company evaluates the creditworthiness of new customers and monitors the creditworthiness of its existing customers to determine whether an event or changes in their financial circumstances would raise doubt as to the collectability of a sale at the time in which a sale is made. Payment terms on sales are generally 30 to 90 days. The Company assessed the promised goods and services in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends. The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company did not deem it necessary to record an allowance for doubtful accounts for probable credit losses at December 31, 2024 and March 31, 2024. At December 31, 2024 and March 31, 2024, the Company has allowances of $ 15,000 27,000
Inventories	Inventories Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value. Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At December 31, 2024 and March 31, 2024, the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $ 239,000 296,000
Recent Accounting Standards	Recent Accounting Standards Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of computation of basic and diluted net loss per share	Schedule of computation of basic and diluted net loss per share Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2024 2023 2024 2023 Numerator: Net loss $ (928 ) $ (866 ) $ (2,681 ) $ (3,768 ) Denominator: Weighted-average number of common shares outstanding: basic and diluted 1,464 546 1,117 351 Net loss per share: basic and diluted $ (0.63 ) $ (1.59 ) $ (2.40 ) $ (10.74 )

Condensed Consolidated Balanc_4

Condensed Consolidated Balance Sheet (Tables)	9 Months Ended
	Dec. 31, 2024
Schedules of balance sheet items
Schedule of inventories, net	Schedule of inventories, net December 31, March 31, 2024 2024 Raw materials $ 1,376,000 $ 1,802,000 Finished goods 2,006,000 1,213,000 Inventories, gross 3,382,000 3,015,000 Less: allowance for obsolete and excess inventory (239,000 ) (296,000 ) Total inventories, net $ 3,143,000 $ 2,719,000
Schedule of lease information	Schedule of lease information December 31, March 31, 2024 2024 Operating leases: Operating lease right-of-use assets $ 119,000 $ 286,000 Operating lease liabilities – current 90,000 198,000 Operating lease liabilities – non-current 29,000 87,000 Other information related to leases is presented below: Nine Months Ended December 31, 2024 Operating lease cost $ 277,000 Other information: Operating cash flows from operating leases (136,000 ) Weighted-average remaining lease term – operating leases (in months) 17.50 Weighted-average discount rate – operating leases 6.00
Schedule of minimum lease payments of operating lease liabilities	Schedule of minimum lease payments of operating lease liabilities For Years Ending March 31, 2025 (excluding the nine months ended December 31, 2024) $ 41,000 2026 65,000 2027 14,000 2028 8,000 Total future minimum lease payments, undiscounted 128,000 Less: imputed interest (9,000 ) Present value of future minimum lease payments $ 119,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of stock options award activity	Schedule of stock options award activity Number of Weighted- Outstanding at April 1, 2024 51,675 $ 62.60 Options exercised (9,250 ) 3.60 Options forfeited (250 ) 3.60 Options expired (63 ) 1,836.29 Outstanding at December 31, 2024 42,112 $ 73.69 Exercisable at December 31, 2024 31,282 $ 95.17
Schedule of restricted stock award activity	Schedule of restricted stock award activity Number of Shares Weighted Average Award Date Fair Value per Share Unvested restricted stock awards outstanding at April 1, 2024 – $ – Restricted stock awards granted 9,538 4.08 Restricted stock awards vested (9,538 ) 4.08 Unvested restricted stock awards outstanding at December 31, 2024 – $ –

Revenue Disaggregation (Tables)

Revenue Disaggregation (Tables)	9 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenues by revenue source	Schedule of disaggregated revenues by revenue source Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Human Care $ 3,052,000 $ 2,461,000 $ 8,886,000 $ 7,286,000 Animal Care 376,000 621,000 1,176,000 1,688,000 Service and Royalty 136,000 56,000 472,000 322,000 $ 3,564,000 $ 3,138,000 $ 10,534,000 $ 9,296,000
Schedule of revenues by geographic region	Schedule of revenues by geographic region Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 United States $ 614,000 $ 868,000 $ 1,930,000 $ 2,214,000 Europe 1,257,000 1,217,000 3,943,000 3,488,000 Asia 579,000 522,000 1,832,000 1,730,000 Latin America 829,000 368,000 2,174,000 1,165,000 Rest of the World 285,000 163,000 655,000 699,000 Total $ 3,564,000 $ 3,138,000 $ 10,534,000 $ 9,296,000

Significant Customer Concentr_2

Significant Customer Concentrations (Tables)	9 Months Ended
	Dec. 31, 2024
Risks and Uncertainties [Abstract]
Schedule of customer concentrations of risk	Schedule of customer concentrations of risk Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Customer A – *% 11 – *% 12 Customer B 23 17 21 15 Customer C 19 13 19 15 The following table shows major customers accounts receivable balances as a percentage of net accounts receivables: December 31, 2024 2023 Customer A 19 13 Customer B – *% 15 Customer C 14 – *% Customer D 25 13 * % Represents less than 10%

Organization and Recent Devel_2

Organization and Recent Developments (Details Narrative)	9 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	The reverse stock split reduced the number of shares of the Company’s common stock outstanding from 21,174,693 to 1,058,447. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the common stock continues to be $0.0001.

Liquidity and Financial Condi_2

Liquidity and Financial Condition (Details Narrative) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 928	$ 610	$ 1,143	$ 866	$ 1,484	$ 1,418	$ 2,681	$ 3,768
Accumulated deficit	197,030						197,030		$ 194,349
Working capital	8,677						8,677		8,829
Liquidity cash balance	$ 5,236						5,236		$ 3,128
Net cash used in operating activities							$ 7	$ (2,550)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details - Earnings per share) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023
Numerator:
Net loss	$ (928)	$ (610)	$ (1,143)	$ (866)	$ (1,484)	$ (1,418)	$ (2,681)	$ (3,768)
Denominator:
Weighted-average number of common shares outstanding: basic	1,464			546			1,117	351
Weighted-average number of common shares outstanding: diluted	1,464			546			1,117	351
Net loss per share: basic	$ (0.63)			$ (1.59)			$ (2.40)	$ (10.74)
Net loss per share: diluted	$ (0.63)			$ (1.59)			$ (2.40)	$ (10.74)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Narrative) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Accounting Policy [Abstract]
Allowances related to potential discounts, returns, distributor fees and rebates	$ 15		$ 15		$ 27
Net realizable value	$ 239		$ 239		$ 296
Equity Option [Member]
Accounting Policy [Abstract]
Anti-dilutive securities excluded from computation of basic loss per share	42	51	42	51

Condensed Consolidated Balanc_5

Condensed Consolidated Balance Sheet (Details - Inventories) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Schedules of balance sheet items
Raw materials	$ 1,376	$ 1,802
Finished goods	2,006	1,213
Inventories, gross	3,382	3,015
Less: allowance for obsolete and excess inventory	(239)	(296)
Total inventories, net	$ 3,143	$ 2,719

Condensed Consolidated Balanc_6

Condensed Consolidated Balance Sheet (Details - Schedule of lease information) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Mar. 31, 2024
Operating leases:
Operating lease right-of-use assets	$ 119	$ 286
Operating lease liabilities – current	90	198
Operating lease liabilities – non-current	29	$ 87
Operating lease cost	277
Operating cash flows from operating leases	$ (136)
Weighted-average remaining lease term - operating leases (in months)	17 months 15 days
Weighted-average discount rate - operating leases	6%

Condensed Consolidated Balanc_7

Condensed Consolidated Balance Sheet (Details - Schedule of minimum lease payments) $ in Thousands	Dec. 31, 2024 USD ($)
Schedules of balance sheet items
2025 (excluding the nine months ended December 31, 2024)	$ 41
2026	65
2027	14
2028	8
Total future minimum lease payments, undiscounted	128
Less: imputed interest	(9)
Present value of future minimum lease payments	$ 119

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) $ in Thousands	9 Months Ended
	Dec. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Aggregated annual salaries	$ 586
Potential severance payments	$ 1,300

Debt (Details Narrative)

Debt (Details Narrative) - Insurance Premium Financing [Member] - USD ($) $ in Thousands	Feb. 06, 2024	Mar. 31, 2024
Short-Term Debt [Line Items]
Debt face amount	$ 373
Debt interest rate	8.42%
Final payment date	Nov. 01, 2024
Debt payment terms	nine monthly installment payments
Periodic payment	$ 42
First installment beginning date	Mar. 01, 2024
Outstanding principal amount		$ 323

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	9 Months Ended
	Nov. 20, 2024	Dec. 31, 2024	Dec. 31, 2023	Aug. 29, 2024	Mar. 31, 2024
Class of Stock [Line Items]
Common stock, shares authorized		50,000,000		50,000,000	24,000,000
Common stock, par value		$ 0.0001		$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized		714,286		714,286	714,286
Convertible preferred stock, par value		$ 0.0001		$ 0.0001	$ 0.0001
Proceeds from sale of stock, net		$ 3,079	$ 1,441
Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Stock issued new, shares	816,894
Proceeds from sale of stock, gross	$ 3,325
Proceeds from sale of stock, net	$ 3,079

Stock-Based Compensation (Detai

Stock-Based Compensation (Details - Stock option award activity) - Equity Option [Member]	9 Months Ended
	Dec. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Outstanding, Beginning Balance | shares	51,675
Weighted-Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 62.60
Number of Shares, Options exercised | shares	(9,250)
Weighted-Average Exercise Price, Options exercised | $ / shares	$ 3.60
Number of Shares, Options forfeited | shares	(250)
Weighted-Average Exercise Price, Options forfeited | $ / shares	$ 3.60
Number of Shares, Options expired | shares	(63)
Weighted-Average Exercise Price, Options expired | $ / shares	$ 1,836.29
Number of Shares, Outstanding, Ending Balance | shares	42,112
Weighted-Average Exercise Price Outstanding, Ending Balance | $ / shares	$ 73.69
Number of Shares, Exercisable | shares	31,282
Weighted-average exercise price, exercisable | $ / shares	$ 95.17

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details-Restricted stock activity) - Restricted Stock [Member]	9 Months Ended
	Dec. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Unvested restricted stock awards outstanding, beginning balance | shares	0
Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, beginning balance | $ / shares	$ 0
Number of Shares, Restricted stock awards granted | shares	9,538
Weighted Average Award Date Fair Value per Share, Restricted stock awards granted | $ / shares	$ 4.08
Number of Shares, Restricted stock awards vested | shares	(9,538)
Weighted Average Award Date Fair Value per Share, Restricted stock awards vested | $ / shares	$ 4.08
Number of Shares, Unvested restricted stock awards outstanding, ending balance | shares	0
Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, ending balance | $ / shares	$ 0

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 13	$ 140	$ 134	$ 447
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation costs	$ 216		$ 216
Weighted average amortization period			1 year 6 months 14 days
Aggregate intrinsic value per share			$ 2.69

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Effective tax rate	(0.10%)	(12.70%)

Revenue Disaggregation (Details

Revenue Disaggregation (Details - Disaggregation of revenue by source) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 3,564	$ 3,138	$ 10,534	$ 9,296
Human Care [Member] | Product [Member]
Disaggregation of Revenue [Line Items]
Revenues	3,052	2,461	8,886	7,286
Animal Care [Member] | Product [Member]
Disaggregation of Revenue [Line Items]
Revenues	376	621	1,176	1,688
Service And Royalty [Member] | Service [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 136	$ 56	$ 472	$ 322

Revenue Disaggregation (Detai_2

Revenue Disaggregation (Details - Revenue by geographic regions) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 3,564	$ 3,138	$ 10,534	$ 9,296
Revenue, Segment Benchmark [Member] | UNITED STATES
Disaggregation of Revenue [Line Items]
Revenues	614	868	1,930	2,214
Revenue, Segment Benchmark [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,257	1,217	3,943	3,488
Revenue, Segment Benchmark [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenues	579	522	1,832	1,730
Revenue, Segment Benchmark [Member] | Latin America [Member]
Disaggregation of Revenue [Line Items]
Revenues	829	368	2,174	1,165
Revenue, Segment Benchmark [Member] | Rest Of The World [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 285	$ 163	$ 655	$ 699

Significant Customer Concentr_3

Significant Customer Concentrations (Details) - Customer Concentration Risk [Member]	3 Months Ended			9 Months Ended
	Dec. 31, 2024		Dec. 31, 2023	Dec. 31, 2024		Dec. 31, 2023
Revenue Benchmark [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		[1]	11%		[1]	12%
Revenue Benchmark [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	23%		17%	21%		15%
Revenue Benchmark [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	19%		13%	19%		15%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				19%		13%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk, percentage					[1]	15%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				14%			[1]
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				25%		13%
[1]% Represents less than 10%